前列腺癌和膀胱癌是最常见的泌尿生殖系统癌症。在过去的 20 年中，针对这些癌症的药物批准量不断增加，但有些患者本身对此类疗法没有反应或没有进展，这凸显了更好地了解疾病生物学和耐药机制的必要性。精准医学试图更好地选择患者接受特定的治疗，尽管该领域已经取得了许多进展，但世界不同地区获得靶向治疗和技术的情况却不同。在本期研讨会专题中，探讨了精准医学和衍生疗法，以及对前列腺癌和膀胱癌治疗的影响，特别关注国际社会在尝试纳入和实施最佳临床实践时遇到的挑战和限制按照全球公认的指南的建议。版权所有 © 2024 Elsevier Inc. 保留所有权利。

Prostate and bladder cancers are the most common genitourinary cancers. In the past 2 decades, there has been increasing drug approval for these cancers, but there are patients who inherently do not respond or progress on such therapies highlighting the need for a better understanding of disease biology and mechanisms of resistance. Precision medicine has attempted to better select patients for specific therapies, although many advances have taken place in this field, access to targeted therapies and technology is distinct in different parts of the world. In this special Seminars issue, precision medicine and derived therapies were explored, as well as the impact on the management of prostate and bladder cancer, specially focusing on the challenges and limitations encountered by the international community when attempting to incorporate and implement the best clinical practice as recommended by worldwide accepted guidelines.Copyright © 2024 Elsevier Inc. All rights reserved.